Differences in health policies for drug availability in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension across Latin America.

Autor: Orozco-Levi M; Respiratory Department Hospital Internacional de Colombia Bucaramanga Colombia.; EMICON Research Group, MINCIENCIAS Bogotá Colombia.; Universidad de Santander (UDES) Bucaramanga Colombia.; Red Colombiana de Hipertensión Pulmonar (HAPred.co) Colombia., Cáneva J; Respiratory Department Hospital Universitario Fundación Favaloro Buenos Aires Argentina., Fernandes C; Pulmonary Division, Pulmonary Circulation Unit, Pulmonary Division, Heart Institute University of São Paulo Medical School São Paulo Brazil., Restrepo-Jaramillo R; University of South Florida Tampa Florida USA., Zayas N; Cardiopulmonary Department National Heart Institute Mexico City Mexico., Conde R; Red Colombiana de Hipertensión Pulmonar (HAPred.co) Colombia.; Critical Medicine and Intensive Care, Pulmonology, Vascular Pulmonary Center Fundación Neumológica Colombiana Bogotá Colombia., Diez M; Cardiology Department Instituto Cardiovascular Buenos Aires Buenos Aires Argentina., Jardim C; Pulmonary Division, Pulmonary Circulation Unit, Pulmonary Division, Heart Institute University of São Paulo Medical School São Paulo Brazil., Pacheco Gallego MC; Red Colombiana de Hipertensión Pulmonar (HAPred.co) Colombia.; Colombian Association of Pulmonology and Chest Surgery Pereira Colombia.; Universidad Tecnológica de Pereira Pereira Colombia.; Universidad Autónoma de las Americas Pereira Colombia.; Respiremos, Respiratory Care Unit Pereira Colombia., Melatini L; Respiratory Medicine Center for Advanced Complexity Respiratory Studies Bahia Blanca Argentina., Valdéz H; Pulmonary Function Department Mexican Social Security Institute Monterrey City Mexico., Pulido T; Cardiopulmonary Department National Heart Institute Mexico City Mexico.
Jazyk: angličtina
Zdroj: Pulmonary circulation [Pulm Circ] 2022 Jan 12; Vol. 12 (1), pp. e12012. Date of Electronic Publication: 2022 Jan 12 (Print Publication: 2022).
DOI: 10.1002/pul2.12012
Abstrakt: Treatment for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension in Latin America differs between countries, with regard to disease etiology, health insurance coverage, and drug availability. A group of experts from Latin America, met to share regional experiences and propose possible lines of collaboration. The available evidence, regional clinical practice data, and the global context of the proceedings of the 6th World Symposium on Pulmonary Hypertension, held in Nice, France, in February 2018, were analyzed. Here, we discuss some priority concepts identified that could guide transnational interaction and research strategies in Latin America: (1) despite being evidence-based, the 6th World Symposium on Pulmonary Hypertension proceedings may not be applicable in Latin American countries; (2) proactive identification and diagnosis of patients in Latin America is needed; (3) education of physicians and standardization of appropriate treatment for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension is vital; (4) our clinical experience for the treatment strategy for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension is based on drug availability in Argentina, Brazil, Colombia and México; (5) there are difficulties inherent to the consultation of patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension, and access to treatment; (6) the importance of data generation and research of Latin American-specific issues related to pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension is highlighted.
(© 2021 The Authors. Pulmonary Circulation published by John Wiley & Sons Ltd on behalf of Pulmonary Vascular Research Institute.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje